Synthesis and Photoinduced Reorientation of Polymethacrylates Comprising Photocrosslinkable Phenylbenzoate Mesogenic Side Groups
摘要:
This paper describes synthesis and photoreaction of photocrosslinkable liquid crystalline (LC) polymethacrylates comprising phenyl benzoate mesogenic side groups attached with a photoreactive end group. All synthesized polymers exhibited a nematic LC nature. Irradiating the polymer film with linearly polarized ultraviolet (LPUV) light induced a negative optical anisotropy due to an axis-selective photoreaction of the mesogenic groups. When the exposed film was annealed at the LC temperature range reversion of the reorientation direction was observed, which was triggered by the photocrosslinked mesogenic groups act as "command in bulk".
Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives
作者:Younghwa Na、Jung-Min Nam
DOI:10.1016/j.bmcl.2010.11.037
日期:2011.1
In order to find potential anticancer drug candidate targeting topoisomerases enzyme, we have designed and synthesized oxiranylmethoxy- and thiiranylmethoxy-retrochalcone derivatives and evaluated their pharmacological activity including topoisomerases inhibitory and cytotoxic activity. Of the compounds prepared compound 25 showed comparable or better cytotoxic activity against cancer cell lines tested. Compound 25 inhibited MCF7 (IC50: 0.49 +/- 0.21 mu M) and HCT15 (IC50: 0.23 +/- 0.02 mu M) carcinoma cell growth more efficiently than references. In the topoisomerases inhibition test, all the compounds were inactive to topoisomerase I but moderate inhibitors to topoisomerase II enzyme. Especially, compound 25 inhibited topoisomerase II activity with comparable extent to etoposide at 100 mu M concentrations. Correlation between cytotoxicity and topoisomerase II inhibitory activity implies that compound 25 can be a possible lead compound for anticancer drug impeding the topoisomerase II function. (C) 2010 Elsevier Ltd. All rights reserved.
NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
申请人:UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA"
公开号:US20190337916A1
公开(公告)日:2019-11-07
Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).